Edition:
India

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

28.00CHF
4:17pm IST
Change (% chg)

CHF0.38 (+1.38%)
Prev Close
CHF27.62
Open
CHF27.80
Day's High
CHF28.08
Day's Low
CHF27.20
Volume
191,218
Avg. Vol
400,399
52-wk High
CHF28.08
52-wk Low
CHF10.00

Latest Key Developments (Source: Significant Developments)

Idorsia Forms Research Collaboration With Roche In Field Of Cancer Immunotherapy
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - IDORSIA LTD ::IDORSIA FORMS RESEARCH COLLABORATION WITH ROCHE IN THE FIELD OF CANCER IMMUNOTHERAPY.PARTIES WILL COLLABORATE ON DISCOVERY OF PRODUCTS THROUGH FORMATION OF A JOINT COMMITTEE, CHAIRED BY IDORSIA.ROCHE WILL PAY IDORSIA AN UPFRONT PAYMENT OF CHF 15 MILLION.ROCHE CAN THEN EXCLUSIVELY LICENSE IDORSIA COMPOUNDS AND COMPOUNDS RESULTING FROM COLLABORATION, FOR FURTHER PAYMENT OF 35 MILLION.IDORSIA WILL BE ELIGIBLE TO RECEIVE ONE-TIME DEVELOPMENT AND REGULATORY MILESTONES OF UP TO CHF 410 MILLION.IDORSIA ALSO BE ENTITLED TO ONE-TIME MILESTONES BASED ON SALES THRESHOLDS, AND TIERED ROYALTIES ON ANNUAL NET SALES.  Full Article

Idorsia ‍Q3 US GAAP operating loss at CHF 68 mln
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - IDORSIA LTD :‍US GAAP OPERATING LOSS IN Q3 2017: CHF 68 MILLION / YTD* 2017: CHF 79 MILLION​.‍NON-GAAP** OPERATING LOSS IN Q3 2017: CHF 61 MILLION / YTD* 2017: CHF 71 MILLION​.‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 160-170 MILLION​.‍AT END OF Q3, IDORSIA'S LIQUIDITY AMOUNTED TO CHF 952 MILLION​.‍9MTH US GAAP NET LOSS AMOUNTED TO CHF 82 MILLION RESULTING IN A NET LOSS PER SHARE OF CHF 0.73​.  Full Article

Idorsia ‍H1 ‍US GAAP operating loss of CHF 11 million​
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - IDORSIA LTD ::‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 180-190 MILLION​.‍US GAAP OPERATING LOSS IN HALF YEAR 2017: CHF 11 MILLION​.‍NON-GAAP OPERATING LOSS IN HALF YEAR 2017: CHF 10 MILLION​.H1 ‍US GAAP NET LOSS PER SHARE AMOUNTED TO CHF 0.11, BASED ON 106 MILLION OF SHARES OUTSTANDING (TIME-WEIGHTED AVERAGE)​.  Full Article

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.